Ποια είναι η τιμή για Applied Molecular Transport Inc. (AMTI)

Η τιμή για Applied Molecular Transport Inc. (AMTI) είναι $0.263

Ποια είναι η κεφαλαιοποίηση αγοράς για Applied Molecular Transport Inc. (AMTI)

Η κεφαλαιοποίηση αγοράς για Applied Molecular Transport Inc. (AMTI) είναι $9.26M

Applied Molecular Transport Inc. (AMTI) Ιστορικό Τιμών

Applied Molecular Transport Inc. (AMTI), a biopharmaceutical company in the clinical development phase, was founded in 2010 and is based in South San Francisco, California. The firm is dedicated to discovering and advancing a pipeline of oral and respiratory biologic drug candidates, designed to address a variety of medical conditions including autoimmune, inflammatory, and metabolic diseases. Among its investigational treatments, AMT-101 stands out as the lead candidate. This orally administered, gastrointestinal (GI)-selective biologic, derived from rhIL-10, is presently in Phase II clinical trials for the management of ulcerative colitis and other related inflammatory indications. AMTI is also further developing AMT-126, another oral, GI-selective biologic that harnesses interleukin 22. This compound is currently undergoing Phase I clinical studies for the treatment of disorders stemming from impaired intestinal epithelial barrier function. The company's innovative technology platform allows for the creation and development of a broad spectrum of oral biologic therapeutic approaches, such as peptides, proteins, antibodies, antibody fragments, and ribonucleic acid (RNA) therapeutics.

Έτος	Απόδοση
2023	-75.75%
2022	-93.48%
2021	-55.27%
2020	0.00%

Έτος

Απόδοση

2023

-75.75%

2022

-93.48%

2021

-55.27%

2020

0.00%

Εταιρεία	Τιμή μετοχής	Μεταβολή 1Έτ%	Χώρα
Vertex Pharmaceuticals Incorporated VRTX.US	$516.59	31.52%	US
Argenx SE ARGX.US	$989.58	51.35%	NL
Lonza Group AG LONN.SW	$736.64	7.19%	CH
Samsung Biologics Co.,Ltd. 207940.KS	$1.07K	-6.40%	KR
UCB S.A. UCB.BR	$255.50	13.38%	BE

Εταιρεία

Τιμή μετοχής

Μεταβολή 1Έτ%

Χώρα